Status: Recruiting
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).
Participants needed: 25
Trial details
Phase: Phase 2Age: 3-31Biological sex: AllType: InterventionalSponsor: New York Medical CollegeUpdated: Aug 8, 2025Locations: 1
Eligibility criteria
Diffuse Large B-Cell Lymphoma [+12]
Patients with newly diagnosed, previously untreated B-NHL. [+5]